Announcement • 4h
Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform Vector Science & Therapeutics Corp. filed a provisional patent application covering a wearable transdermal delivery platform that uses a pulsed magnetic field to transport peptide therapeutics through the skin to targeted tissue without injection, electrical stimulation, or needles. The platform is designed to solve a longstanding challenge in peptide medicine: getting therapeutic molecules past the skin barrier and into the tissue where they are needed. The system uses a proprietary magnetic patch worn on the body to physically guide microscopic peptide carriers through skin layers to the target site. Once there, the carriers are designed to release their payload only in the presence of biological signals associated with disease or inflammation, leaving healthy surrounding tissue unaffected. A key feature of the platform is its built-in delivery confirmation. The system is designed so that clinicians and patients can verify that the peptide reached its intended destination through both real-time imaging and a visible indicator in the patch itself that changes in response to successful delivery. The carriers are also engineered to exit the body naturally within 72 hours, addressing a core safety concern associated with nanoparticle-based therapies. The platform is designed for broad applicability across conditions characterized by tissue inflammation, degeneration, or injury which is consistent with Vector's focus on non-invasive, non-systemic intervention for musculoskeletal and regenerative medicine indications. Vector intends to formulate the new delivery technology at the LyoGenesis Plus manufacturing facility in Mequon, Wisconsin, under its manufacturing partnership agreement. This filing adds to Vector's growing IP portfolio, which now totals 15 patents spanning non-invasive transdermal drug and peptide delivery, including the recently filed hybrid phoresis platform for delivery of BPC-157 and TB-500 to musculoskeletal and peripheral nerve targets, and extending to post-operative pain management, wound healing, and targeted electrochemotherapy. Together, these filings reflect Vector's commitment to building a proprietary, multi-platform foundation in localized, non-systemic therapeutic delivery. The Company is monitoring the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, which is expected to address the regulatory status of BPC-157, TB-500, and related peptides relevant to Vector's delivery platforms. Announcement • Jun 13
Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform Vector Science & Therapeutics Corp. announced the appointment of Dexter Fowler as Chief Athletic Officer for Valor, its sports medicine division built to bring Vector’s transdermal peptide platform to elite athletes and the sports medicine professionals who care for them. Fowler, a 2016 World Series Champion and Olympic bronze medalist, will lead athlete engagement and onboarding across professional sports. Fowler spent fourteen seasons as a center fielder and leadoff hitter for the Colorado Rockies, Houston Astros, Chicago Cubs, St. Louis Cardinals, and Los Angeles Angels. He is best known for leading off Game 7 of the 2016 World Series with a home run that ignited the Cubs’ first championship in 108 years. After retiring, he founded 400 Ventures, an athlete and entertainment management firm, and holds ownership stakes in AFC Bournemouth and Lorient FC. Announcement • Jun 09
Vector Science & Therapeutics Corp. Announces Appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors Vector Science & Therapeutics Corp. announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors. Valor is a newly formed division of Vector, focused on developing relationships in the professional and elite athlete market and building the commercial infrastructure to support Vector's advancing transdermal peptide delivery platform. Drake will lead Valor's market development efforts, initially promoting Vector's line of pharmaceutical-grade peptides, manufactured under cGMP standards in an FDA-licensed facility and tested to the highest standards for safety and purity, while establishing a network of sports medicine clinicians, trainers, and elite athlete advocates ahead of the Valor transdermal delivery platform's commercial launch. Drake brought more than a decade of leadership building high-performance commercial teams across multiple countries, with a track record of managing relationships with top athlete influencers and multimedia-driven platforms that positions him well for the relationship-first mandate Valor requires. Drake was an early investor in Vector and has spent over a decade building high-performance commercial teams responsible for more than $150 million in sales across multiple countries, consistently ranking in the top 1% of every organization he has been part of. 
